Update notification · 14.08.2026
Supply shortage: ZYPADHERA 210 mg Depot-Injektionssuspension
Affected country: Germany · Reported period: 08.09.2026 – 28.10.2026 · Active ingredient: Olanzapinembonat-Monohydrat
Notice context
A supply shortage has been recorded for ZYPADHERA 210 mg Depot-Injektionssuspension in Germany. The stated reason is “Production problem”. The notice concerns the active ingredient Olanzapinembonat-Monohydrat and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →